Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OE226-iNK cells
- Development stage
- Phase 1
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
OE226-iNK cells are **induced pluripotent stem cell-derived natural killer (iPSC-NK) cells engineered to overexpress CD226**. CD226 is an activating receptor on NK cells that recognizes ligands such as CD112 and CD155 on tumor cells, leading to NK cell activation and cytotoxicity. Acute myeloid leukemia (AML) cells can induce CD226 downregulation as an immune escape mechanism. By overexpressing CD226, OE226-iNK cells demonstrate **enhanced cytotoxic function and cytokine release against AML cells**. Preclinical models show that OE226-iNK cells significantly reduce leukemia burden, prolong survival, and diminish systemic inflammation compared to unmodified (control) iPSC-NK cells, indicating their **potential as an off-the-shelf immunotherapy for AML and other CD226 ligand-expressing cancers**[1].
- Other names
- CD226 overexpression iPSC-derived NK cellsCD-226 overexpression iPSC-derived NK cellsCD 226 overexpression iPSC-derived NK cells
02
Targets
CD226 (DNAX accessory molecule 1)NECTIN2 (Nectin cell adhesion molecule 2)
Beyond the preview
Go deeper on OE226-iNK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OE226-iNK cells.